TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
TScan Therapeutics (Nasdaq: TCRX) will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 11:50 a.m. ET in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics (Nasdaq: TCRX) will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 11:50 a.m. ET in Boston.
The hybrid presentation includes an analyst Q&A and a live webcast via the company’s Events and Presentations page, with an archived replay available for 90 days.
Details
News Market Reaction – TCRX
On Feb 25, the day this news came out, TCRX closed 5.71% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
Key Figures
- Conference edition
- 46th Annual
- TD Cowen Health Care Conference
- Conference date
- March 4, 2026
- Presentation schedule at TD Cowen conference
- Presentation time
- 11:50 a.m. ET
- Scheduled presentation time at conference
- Webcast replay period
- 90 days
- Archived replay available after the event
Historical Context
-
Updated ALLOHA Phase 1 data with improved survival and no DLTs.
-
Announcement of virtual KOL event on ALLOHA data and heme market.
-
Q3 2025 results with higher revenue and extended cash runway.
-
Participation in Guggenheim healthcare innovation conference webcast.
-
Pivotal design for TSC-101 plus workforce reduction and cost savings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
t cell receptor medical
tcr-t medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 2026 at 11:50 a.m. Eastern Time.
A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed multiple TCR-T therapy candidates for solid tumors and is currently developing methods for in vivo engineering using these candidates. The Company is also applying their target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.
Contacts
Troy Neubecker
TScan Therapeutics, Inc.
Investor Relations
857-399-9517
tneubecker@tscan.com
Caileigh Dougherty
Media Contact
857-399-9890
cdougherty@tscan.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.